Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release
September 20, 2017 08:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced that it has filed an Abbreviated New Drug Application (ANDA) with...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information
June 14, 2017 16:58 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
May 30, 2017 08:42 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
February 07, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Reports On SequestOx™ FDA End-of-Review Meeting
January 23, 2017 08:18 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported the Company received official minutes from its December 21, 2016...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®
January 17, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study...
Elite Provides Update on SequestOx™ New Drug Application
December 22, 2016 12:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
June 15, 2016 16:19 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increased 150% Conference Call Scheduled for Monday, June 20 at 11:00 AM EDT NORTHVALE, N.J., June 15, 2016 ...
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
June 09, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing...
Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
June 09, 2014 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human...